Mesenchymal Stem Cell Suspension for Acute Stroke Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute stroke, such as thrombolytic therapy, have limited success in improving patient health, and there is a need for a clinically safe and effective cell-based composition for treating acute stroke in humans.
Innovation Solution
A cell-based composition comprising a suspension of mesenchymal stem cells in crystalloid, with a concentration of 0.01 million to 3.0 million cells/ml, administered intravenously in a therapeutically effective amount of 0.25 million to 3.0 million cells/kg body weight, derived from sources like human umbilical cord, bone marrow, or fat tissue, and characterized by adherence to plastic, specific antigen markers, and tri-differentiation ability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombolytic therapy is used for acute stroke treatment, then the treatment can be administered conventionally, but the success rate in improving patient health is limited
Solution Approach 1:
The patent changes the fundamental parameter of treatment modality from chemical thrombolytic therapy to biological cell-based therapy using mesenchymal stem cells. This parameter change enables the treatment to achieve therapeutic effects through cellular mechanisms (differentiation, immunomodulation, neuroprotection) rather than chemical fibrinolytic action, thereby overcoming the limited success rate of conventional thrombolytic therapy while maintaining clinical applicability
Solution Approach 2:
The patent introduces mesenchymal stem cells as an intermediary substance that mediates the treatment effect. These cells act as biological mediators that can differentiate into neuron-like cells, modulate immune responses, and provide neuroprotection, thereby establishing a new therapeutic pathway that overcomes the limitations of direct chemical thrombolysis
2Reliability
If mesenchymal stem cells are used for acute stroke treatment, then therapeutic effectiveness is improved, but clinical safety and efficacy data in humans is lacking
Solution Approach 1:
The patent performs preliminary actions by conducting comprehensive preclinical studies in animal models (rat stroke models) before human application. The patent document details extensive in vivo and in vitro experiments that have already validated the safety and efficacy of mesenchymal stem cells, thereby preparing and accumulating necessary data to reduce the information gap for human clinical trials
Solution Approach 2:
The patent establishes feedback mechanisms through systematic monitoring and evaluation of treatment outcomes in preclinical models. By implementing rigorous assessment protocols (neurological scoring, functional evaluation, safety monitoring) in animal studies, the patent creates a feedback loop that generates evidence to inform and support future human clinical applications, thereby addressing the lack of clinical data
3Ease of operation
If intravenous administration of mesenchymal stem cells is performed, then the treatment is non-invasive and easier to administer, but the cellular concentration and delivery efficiency must be optimized
Solution Approach 1:
The patent optimizes the parameter of cellular concentration by establishing specific dosage ranges (0.25 to 3.0 million cells/kg body weight) and suspension concentrations (0.01 to 3.0 million cells/ml). This parameter optimization ensures that the intravenous administration delivers therapeutically effective doses while maintaining ease of administration through standardized cell preparation protocols
Solution Approach 2:
The patent implements dynamic adjustment capabilities in the cell-based composition system by allowing flexible dosing based on patient body weight and clinical condition. The administration protocol can be dynamically adjusted within the specified concentration ranges to optimize delivery efficiency while maintaining the non-invasive intravenous route, thereby balancing ease of operation with manufacturing precision
Data Source
AI summary
A method for the treatment of acute stroke in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.